Organigram Global Inc

Organigram Global Inc (OGI) Stock Analysis

$0.930

-0.034 (-3.65%)At close

Loading chart…
High
0.980
Open
0.980
VWAP
0.93
Volume
1.66M
Mkt Cap
164.80M
Low
0.890
Amount
1.55M
EV/EBITDA, TTM
3.03

Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd.

AI analysis of Organigram Global Inc (OGI)

Buy

OrganiGram Holdings Inc is a good buy right now due to its recent strong performance, with a current price of 0.9651 and a significant gross margin of 23.06% in Q3 2026. The stock has shown a 5-day change of +2.78% and a projected trajectory indicating a potential increase of +105.64% based on historical patterns. However, investors should be cautious of the risk posed by a high forward P/E ratio of 14.66, which may indicate overvaluation if growth does not materialize as expected.

Valuation Metrics

The current forward P/E ratio for Organigram Global Inc (OGI) is 15.02, compared to its 5-year average forward P/E of 1.47.

Forward P/E

Fair
5Y Average P/E
1.47
Current P/E
15.02
Overvalued
49.92
Undervalued
-46.97

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-34.26
Current EV/EBITDA
3.03
Overvalued
201.70
Undervalued
-270.23

Forward P/S

Undervalued
5Y Average P/S
1.59
Current P/S
0.30
Overvalued
2.78
Undervalued
0.39

Alphio AI Price Scenarios for OGI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OGI

$1.86

Scenario price

B

Base

Base · 50%OGI

$1.64

Scenario price

B

Bear

Bear · 25%OGI

$1.37

Scenario price

Events Timeline

2026-11-03 (ET)

16:30:00

Apple Warns of Margin Drop, Mixed Day for Markets

12:00:00

Apple Warns of Margin Drop, Markets Mixed

09:30:00

Organigram to Acquire Aurora at C$7.80 per Share, Valuing Transaction at Approximately C$561 Million

09:30:00

Organigram to Acquire Aurora Cannabis for C$7.80 per Share

08:30:00

Organigram Holdings Trading Halted, News Pending

News

OGI FAQ — answered by Alphio AI

Organigram Global Inc. is focused on producing cannabis for adult recreational consumers, as well as developing international business partnerships. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT, Collective Project, Fetch and DEBUNK. It operates facilities in Moncton, New Brunswick and LacSuperieur, Quebec, with an edibles manufacturing facility in Winnipeg, Manitoba. It operates two additional cannabis processing facilities in Southwestern Ontario: one in Aylmer and the other in London. The facility in Aylmer houses CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London is optimized for labeling, packaging, and national fulfillment. Its subsidiaries include Organigram Inc. and Motif Labs Ltd. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

OrganiGram Holdings Inc is a good buy right now due to its recent strong performance, with a current price of 0.9651 and a significant gross margin of 23.06% in Q3 2026. The stock has shown a 5-day change of +2.78% and a projected trajectory indicating a potential increase of +105.64% based on historical patterns. However, investors should be cautious of the risk posed by a high forward P/E ratio of 14.66, which may indicate overvaluation if growth does not materialize as expected.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading